OBOlesya P. Balitska

Olesya P. Balitska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olesya P. Balitska has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The clinical and economic analysis of the need for medicines in a healthcare institution serving the population under the medical guarantees program

    by O. P. Kohut, Yu. O. Tomashevska, N. A. Verba

    In the current conditions of the healthcare reform in Ukraine, the effective use of resources of healthcare institutions (HCIs) and the rational pharmaceutical provision require a systematic analysis of the need for medicines as a key factor in ensuring the continuity of the treatment process, clinical efficiency and economic feasibility of budget expenditures. Aim. To conduct a clinical and economic analysis of the need for medicines in HCIs serving the population under the Medical Guarantees Programs. Materials and methods. The list of medicines submitted by the departments of the University Clinic (UC) of the Vinnytsia National Medical University named after M. I. Pyrohov, the National List of Essential Medicines (2025), the State Formulary of Medicines, the seventeenth edition (2025), were used. The research methods applied were retrospective, system-analytical, mathematical-statistical, clinical and economic analysis (frequency and ABC). Results and discussion. As a result of the analysis of the lists of medicines for procurement by the UC for the period studied, the need by international non-proprietary names (INN) in the place of service provision (PSP) No. 1 amounted to 114 items, and there were 52 items in PSP No. 2. The total amount of the need for medicines was 956,484 UAH, namely: for PSP No. 1 – 319,292.25 UAH, for PSP No. 2 – 637,191.32 UAH. The largest expenditures were planned for 0.9 % Sodium chloride, 200 ml, – 166,460.00 UAH (17.4 %), Medipred, 16 mg, tab. – 54,894.00 UAH (5.74 %), Paracetamol 10 mg/ml, 100 ml, – 53,912.00 UAH (5.64 %). The total number of medicines indicated by HCI specialists for procurement by the UC for both PSPs was 44,619. By the frequency of submitted data, the leading medicines in the procurement lists were 0.9 % Sodium chloride, 200 ml, – 7,000 times, Medipred, 4 mg, tab., Magnesium sulfate, 250 mg/ml, 5 ml amp., Dexamethasone, 4 mg/ml, 1 ml amp., – 3,000 times each respectively, and Medipred, 16 mg, – 2,100 times. Based on the results of the comparative characteristics of the frequency and ABC analysis of the medicines studied, 0.9 % Sodium chloride, 200 ml, became the most frequent and most expensive item. Methotrexate, 10 mg/ml, 1 ml syringes, and Linezolid, 2 mg/ml, 300 ml vials, demonstrated low frequency at high cost. Conclusions. The features of the structure of the need for medicines and the distribution of financial expenditures have been found. The presence of 0.9 % Sodium chloride, 200 ml, among the leaders by frequency and cost is expedient since the UC provides for inpatient patients, and infusion therapy is an integral part of the treatment process.

  • Open Access

    Assessment of the availability of medicines under the reimbursement program for patients with type 2 diabetes in Vinnytsya region

    by O.P. Balicka, Yu.O. Tomashevska, M.V. Balynska, V.S. Zlahoda

    Aim: assessment of drug availability under the reimbursement program for patients with type 2 diabetes in Vinnytsya region. Materials and methods of research. A set of regulatory legal acts on the organization of pharmaceutical support for patients with diabetes in Ukraine; data from scientific literature on the problems of organizing effective pharmaceutical care for patients with diabetes in Ukraine and in the world; patients with type 2 diabetes, doctors who provide primary medical care (family doctors), the State Register of Drugs (2024), the official Internet resource of the National Health Insurance Fund. Methods: historical; logical; comparative, semantic, bibliographical; graphical; mathematical and statistical. Results. As a result of the study, a comprehensive assessment of the availability of drugs under the reimbursement program for patients with type 2 diabetes was carried out, which included an analysis of the current state of provision for patients with type 2 diabetes and an analysis of e-prescriptions created under the reimbursement program for 2019-2024. It was found that 45 names were registered by trade name (TN) - 80.0 % based on metformin (A10BA02), 7 names by TN (13.0 %) based on gliclazide (A10BB09), and 3 names by TN (7.0 %) based on glibenclamide (A10BB01). According to the results of the analysis of e-prescriptions created under the reimbursement program over the past 6 years, the leader among diseases in terms of the number of prescriptions were cardiovascular diseases – 2 481 626 e-prescriptions. The total number of prescriptions over the six years was 744 952. Metformin became the leading drug in terms of prescription frequency – 540 384 e-prescriptions were written for it. The largest number of prescriptions was written in cities – 431 821, which is more than 50 % of the total. In rural areas, this figure is significantly lower – 199 180, and in urban settlements – 113 951, which indicates an uneven distribution of access to treatment and, probably, a higher prevalence of applications in cities. There is a trend towards an increase in the number of prescriptions issued (from 103 711 e-prescriptions in 2019 to 140 412 e-prescriptions in 2024), which may indicate improved accessibility of medical services and medicines for patients. Conclusions. As a result of the study, a positive trend was established in the number of e-prescriptions issued for oral hypoglycemic drugs in the Vinnytsya region, which indicates an increase in the availability of pharmaceutical care for chronic patients with type 2 diabetes and an improvement in the healthcare system as a whole.

  • Open Access

    The frequency and VEN analysis of medical prescriptions for patients with duodenal ulcer disease in healthcare institutions

    by O. P. Balitska, M. V. Balynska, V. S. Zlahoda, V. V. Hutsol, V. M. Koval, Yu. O. Tomashevska, S. O. Kryvoviaz

    Aim. To perform the frequency and VEN analysis of medical prescriptions for patients with duodenal ulcer disease (DUD) in a healthcare institution. Materials and methods. Depersonalized information base containing data from 112 histories of patients with DUD who were treated in one of the healthcare institutions in Vinnytsia, prescription sheets, the National List of Essential Medicines, the Unified Clinical Protocol of Primary and Specialized Medical Care “Peptic ulcer of the stomach and duodenal ulcer in adults and children” (2023), the State Formulary of Medicines (2023) were used. Research methods such as retrospective, system-analytical, frequency and VEN analysis were applied. Results. As a result of the frequency and VEN analysis conducted during the study period, doctors prescribed a total of 48 active substances by INN and 109 drugs by trade names (TN). A total of 817 drugs were prescribed by TN. According to the results of this analysis, it was found that the largest number of prescriptions fell on proton pump inhibitors of different generations (21.3 % of all prescriptions) and multienzyme drugs (15.06 % of all prescriptions). For the eradication of Helicobacter pylori, agents for the treatment of peptic ulcer and gastroesophageal reflux disease, combinations for the eradication of Helicobacter pylori were prescribed (14.89 % of all prescriptions). There were also many prescriptions from groups of drugs affecting the digestive system (13.89 %). For the treatment of concomitant pathologies, drugs used to treat the liver and biliary tract (4.28 %), intestinal anti-inflammatory drugs (2.08 %), anti-anemic drugs (1.46 %), antibacterial drugs, antibiotics, hypolipidemic, hypnotic, sedative drugs, antidepressants, etc., were prescribed. It was proved that the main of pharmacotherapy of DUD was etiological and pathogenetic therapy. According to the VEN analysis, 8 drugs (17 %) were included in category V, 22 drugs (46 %) – in category E, and 18 drugs (37 %) – in category N, out of 48 drugs by INN. Conclusions. Therefore, the study conducted showed that a significant number of prescriptions and financial resources were directed to the use of secondary drugs that were not included in the regulatory legal acts regulating the pharmaceutical provision of patients with DUD.

  • Open Access

    The analysis of medical prescriptions for patients with duodenal ulcer in hospital setting

    by O. P. Balitska, M. V. Balynska, V. S. Zlahoda, O. D. Haiday, O. D. Blahun, V. O. Ischenko

    Aim. To analyze medical prescriptions for patients with duodenal ulcer disease in hospital setting, to determine the compliance of the treatment with the current treatment protocols. Materials and methods. We used 102 case histories, medical prescriptions of the Gastroenterology Department of the Clinical Regional Hospital named after M.I. Pirogov, Unified Clinical Protocol of the primary and specialized medical care “Peptic ulcer of the stomach and duodenum in adults and children”, the State Formulary of Medicines of Ukraine, the nomenclature of drugs for the treatment of duodenal ulcer, the official online resource tabletki.ua. Statistical, analytical and comparative, systematic, logical, graphic and mathematical-statistical methods were applied. Results and discussion. As a result of the study conducted, an analysis of drug prescriptions for patients with duodenal ulcer was carried out at the premises of the Gastroenterology Department of the Clinical Regional Hospital named after M. I. Pirogov. Over a period of 1 year and 3 months, 102 patients with the main diagnosis of duodenal ulcer were treated. According to the data obtained from the histories of diseases, men (94 %) aged 30-40 years were most often ill. The average duration of bed days was 5 days. The most common concomitant diseases were pancreatitis, GERD (non-erosive, endoscopically positive), hepatitis, duodenal bile reflux, Oddi sphincter dysfunction (pancreatic type). Two groups of drugs were prescribed according to the ATC classification for pathogenetic and symptomatic treatment: group A – drugs affecting the digestive system and metabolism (71.43 %) and group J – antimicrobial drugs for systemic use (28.57 %). Among the producing countries, foreign-made drugs prevailed – 62.4 %. During the study period, doctors prescribed 63 active substances by INN and 109 drugs by TN. In accordance with the Unified Clinical Protocol, the number of INN drugs was 18, 39 drugs by TN, and the State Formulary included drugs of 48 INN and 80 TN. During the study period, 24 drugs by TN for the pathogenetic treatment (eradication therapy) and 18 drugs by TN for the symptomatic treatment were prescribed. The prescription of drugs for the pathogenetic and symptomatic treatment was scientifically substantiated and included in the current normative documentation for the provision of patients with duodenal ulcer. When conducting the eradication therapy the leading drugs were Omeprazole (66 prescriptions), De-nol (55 prescriptions), Ezonexa (29 prescriptions), Controlok (26 prescriptions), Pilobact Neo (24 prescriptions). To prevent dysbiosis, such drugs as Enterol (8 prescriptions), Enterogermina forte (7 prescriptions) were most often prescribed. To relieve the symptoms of duodenal ulcer, Mebsyn Retard (24 prescriptions), Trimspa (19 prescriptions), Neospastil (17 prescriptions) were applied. Conclusions. Therefore, the medical care of patients in hospital setting is expedient and corresponds to the current Treatment Protocols.


  • Open Access

    The analysis of the range of antihistamines at the pharmaceutical market of Ukraine

    by О. P. Balitska, V. S. Zlahoda, O. D. Haiday, O. D. Blahun, M. A. Artemchuk

    Aim. To analyze the range of antihistamines (AH) at the pharmaceutical market of Ukraine. Materials and methods. The analysis of the range of drugs was carried out in accordance with the State Register of Medicines of Ukraine as of February 2023, the weekly “Apteka” to determine the data of actual sales of AH. Statistical, frequency and graphic methods were used in the analysis. The information was processed using Microsoft Office Excel. Results. As a result of the frequency analysis, it was found that the pharmaceutical market of Ukraine as of February 2023 of AН for systematic use was represented by 170 trade names (TN) and 135 international non-proprietary names (INN). The leaders by INN were Desloratadine (34 TN) and Levocetirizine (26 TN). According to the State Register of Medicines of Ukraine as of February 2023, there were different drug forms, namely: tablets, solutions, drops, syrups, dragees and granules for the preparation of oral suspension. The largest share was AH in the form of tablets (70.59 %), solutions, drops, and syrups accounted for almost the same percentage (10 %, 9,41 %, 8,82 %), and 2 % of AH were registered in the form of dragees. The ratio of AH producing countries at the pharmaceutical market of Ukraine by TN was also determined. It was found that among the dosage forms presented, 62 % were of foreign production. AH of domestic production were 38 %; moreover, the largest market share (19 %) was produced by LLC Pharmaceutical Company “Zdorovye”. According to the results of the official data of weekly “Apteka” on the actual consumption of AH, it was found that AH of the second generation were the most popular both by INN and TN. It is due to their pharmacokinetic properties and the optimal price/effectiveness ratio. Conclusions. Based on the above, we can conclude that the pharmaceutical market of Ukraine is represented by a wide range of AH in various forms of production and various manufacturers. This leads to a wide choice of drugs of this group among the population, pharmaceutical and medical professionals.

  • Open Access

    Marketing analysis of medicines based on the active substance St. John's wort (Hypericum perforatum L.).

    by L. V. Kremenska, V. S. Zlahoda, S. D. Kryklyva, O. P. Balitska, M. V. Balynska, L A. Klimas

    Annotation. Medicinal plant St. John's wort (Hypericum perforatum L) is widely used in medicine in many countries of the world as a natural antidepressant, and due to its antitumor and cytotoxic effects. Research is being actively conducted on the use of St. John's wort in other areas of medicine. The purpose of the study is a marketing analysis of medicinal products that are registered in Ukraine with the active ingredient St. John's wort (Hypericum perforatum L.). The research material was data from the State Register of Medicinal Products of Ukraine in 2022, declared wholesale and retail prices in Ukraine as of October 2022. The research methods were frequency and content analysis. According to the ATS classification of medicinal products with the active ingredient St. John's wort on the pharmaceutical market of Ukraine, the presence of 4 groups has been established: A - agents affecting the digestive system and metabolism, N - agents affecting the nervous system, L - antineoplastic and immunomodulating agents, G-agents affecting the genitourinary system and sex hormones. According to the declared wholesale and retail prices as of October 2022, various forms of release of medicines were established, namely tablets, capsules, collections, solutions, herbs, drops, tinctures, syrups and balms. The cost of various dosage forms with the active ingredient St. John's wort was determined. It was established that the cost of 1 package ranges from UAH 10.57 to UAH 474.21. As a result of the content analysis, an assortment of medicinal forms registered on the territory of Ukraine and consisting of 27 trade names was established. The medical fees are presented by 5 TN and occupy 18.52% of the pharmaceutical market of Ukraine. According to the ATS classification, the largest group of drugs with the active ingredient St. John's wort is group A – drugs that affect the digestive system and metabolism. During the analysis of manufacturers of modern dosage forms it was established that the ratio of domestic and foreign production is 3:1, where domestic dosage forms make up 74%. In the future, it is planned to carry out a more detailed content analysis of drugs, taking into account accessibility for the consumer/patient and the development of new complex drugs that based on St. John's wort.

  • Open Access

    The marketing analysis of paracetamol and ibuprofen for the treatment of acute respiratory infections in Ukraine

    by О. P. Balitska, V. S. Zlahoda, Yu. M. Hryhoruk, Yu. M. Polischuk, О. D. Haiday

    Aim. To conduct the marketing analysis of medicines registered in Ukraine with the international nonproprietary name (INN) – ibuprofen and paracetamol for the treatment of acute respiratory infections (ARI). Materials and methods. The data of the State Register of Medicines of Ukraine, the data of the Register of wholesale and selling prices for medicines in Ukraine as of March 2021 were used. Bibliosemantic, marketing, analytical, graphic, frequency and descriptive analyses were applied. Results. The marketing analysis of ibuprofen and paracetamol revealed their different drug forms, namely children’s forms were presented in the form of suspensions, syrups, suppositories, while adults forms – in the form of tablets, capsules, sachets, injectable dosage forms. It was found that ibuprofen was represented at the pharmaceutical market of Ukraine by 10 trade names (TN) in the form of tablets, 5 TN in the form of capsules. 7 TN of Paracetamol were presented in the form of a solution for injection at the pharmaceutical market of Ukraine, 10 TN were in the form of tablets, and 2 TN were in the form of suppositories. The cost of ibuprofen and paracetamol was studied: the cost of 1 package of children’s medicines ranged from 17.2 to 102.31 UAH, ibuprofen – from 16.2 to 150 UAH, paracetamol – from 15.09 to 980 UAH. The most expensive paracetamol was represented by the trade name Parafusiv (paracetamol, 10 mg/ml for inf., 100 ml vial, 10 mg/ml, No.10 (Portugal)). Conclusions. The marketing research of ibuprofen and paracetamol has shown their diversity at the pharmaceutical market of Ukraine. These drugs are represented by a wide range of trade names, drug forms, manufacturers and a wide range of prices. The country-manufacturer of all drugs presented is Ukraine (73 %).


  • Open Access

    The pharmacoepidemiological analysis of the influenza pharmacotherapy in Ukraine

    by O. Balitska, V. Zlahoda, Yu. Hryhoruk, O. Cordon

    Influenza and other acute respiratory viral infections (ARIs) are the most common among human diseases that require timely medical attention and treatment with the most effective drugs. The aim of the study is pharmacoepidemiological analysis of drugs for the treatment of influenza registered in Ukraine. Materials and methods of research. The study was based on data from the State Register of Medicines of Ukraine, information on the results of the epidemic season of influenza and acute respiratory infections of the Center for Public Health of the Ministry of Health of Ukraine, declared drugs under the International Nonproprietary or Common Name in Ukraine as of January 2021. Methods: retrospective, descriptive and frequency analyzes. Results and discussion. A pharmacoepidemiological analysis of influenza drugs in Ukraine was conducted. It was found that the incidence of influenza and SARS during the study period decreased by 3.1% of the total population. Fatalities due to influenza and SARS increased by 41 cases during the study period, which may be related to the coronavirus pandemic. According to the results of a marketing study of antiviral drugs, it was found that the largest share in the structure of registered trade names are interferons (11 trade names). Conclusions. The analysis of the market showed that among the antiviral drugs registered in Ukraine for the studied period the dominance of domestic drugs is noted - 54% (respectively of foreign origin - 46%). Analysis of the distribution of domestic analogues of antiviral drugs by manufacturers found that the largest (5 and 4 TN) belongs to LLC "Research and production company" Interpharmbiotek and FZ "Biopharma" Ltd., Ukraine, Bila Tserkva. Key words: influenza; pharmacoepidemiological analysis; antiviral drugs

  • Open Access

    The assessment of the rationality of the pharmacotherapy of acute respiratory viral infection in the outpatient practice

    by O. P. Balitska, Yu. M. Hryhoruk, M. A. Artemchuk, V. S. Zlahoda V. S.

    Acute respiratory viral infections (ARI) and influenza occupy a leading place in the structure of the overall morbidity of the population in most countries. Aim. To assess the rational prescription of drugs for etiotropic therapy of ARI in the outpatient practice. Materials and methods. The following materials for research were used: case histories; treatment sheets; the Unified clinical protocol of primary care for adults and children “Acute respiratory infections”; data of the State Formulary of Medicines as of January 2021; the Register of wholesale prices; the weekly “Apteka” (Pharmacy). The methods of retrospective, descriptive, frequency, and VEN-analysis were applied. Results. According to the research results, using patient histories, it was found that family doctors prescribed 67 drugs by trade names. For etiotropic therapy, 24 drugs were used; it was 37 % of the total number, and 63 % – for symptomatic therapy. Such drugs as Amizon, Aflubin, Amixin, Resistol, Umkalor were for etiotropic therapy (more than 5 prescriptions). None of these drugs is included in the State Formulary of Medicines and the Unified clinical protocol for the treatment of influenza and SARS. Thus, these drugs are without the proven efficiency, safety and cost-effective use. Conclusions. The study conducted has shown that the drugs prescribed most often do not have an evidence base of efficacy and safety; none of the most frequently prescribed drugs is included in the State Formulary of Medicines and the Unified clinical protocol. A direct relationship between an increase in the number of prescriptions and an increase in price has been proven. Key words: acute respiratory viral infections; influenza; frequency analysis; VEN-analysis; family doctor.


  • Open Access

    Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer

    by Olesya P. Balitska, Tamara A. Germanyuk, Yuliia M. Hryhoruk, Tatiana I. Ivko, Yuliia O. Tomashevska, Vasyl M. Koval, Yuliia M. Polishchuk, Viktoriia V. Hutsol, Myhailo A. Artemchuk

    Aim. The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on literature. Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors analysis. Methods. Descriptive, statistical, retrospective. Results and Conclusion. According to the clinical random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 week repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9±6.2), Pariet + Amoxicillin + Clarythromycin (83±2.6), Kontrolok + Amoxicillin + Clarythromycin (100±1.3), Pultset + Amoxicillin + Clarythromycin (88±4.1), Nolpaza + Amoxicillin + Clarythromycin (72±4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7±3.8), Neksium + Amoxicillin + Clarythromycin (96.1±3.1).